Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.32 |
| ▸ | ESR1 | P03372 | 6/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288111 | 0.80 | IDH1 (0.38) | CYP3A4FFAR4SLC18A3ESR2MRGPRX4 | |
| SCHEMBL4289255 | 0.77 | CYP3A4 (0.47) | CYP3A4FFAR4SLC18A3ESR2MRGPRX4 | |
| SCHEMBL4286675 | 0.76 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL27746708 | 0.75 | CYP4F2 (0.38) | FFAR4ESR2 | |
| SCHEMBL27767757 | 0.73 | CYP4F2 (0.34) | ESR2 | |
| SCHEMBL27767700 | 0.73 | THRA (0.44) | CYP3A4FFAR4ESR2ESR1MRGPRX4 | |
| SCHEMBL4285009 | 0.69 | CYP3A4 (0.36) | CYP3A4FFAR4SLC18A3ESR2 | |
| SCHEMBL4285589 | 0.67 | BACE1 (0.39) | CYP3A4ESR2ESR1CYP2C9CYP2D6 | |
| SCHEMBL4286864 | 0.66 | IDH1 (0.41) | CYP3A4 | |
| SCHEMBL4289375 | 0.65 | HTR2A (0.41) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | CYP3A4 534/4885AOC3 2793/4885FFAR4 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.